FDA or­ders a par­tial hold on Epizyme’s lead can­cer drug tazeme­to­stat fol­low­ing T-cell lym­phoma case

Epizyme $EPZM is in some hot wa­ter this evening af­ter the biotech re­vealed a par­tial clin­i­cal hold on its cru­cial pro­gram for tazeme­to­stat.

The Cam­bridge, MA-based biotech was forced to slam the brakes on any en­roll­ment for its clin­i­cal tri­als of the drug for now as in­ves­ti­ga­tors sort out a pe­di­atric case of sec­ondary T-cell lym­phoma.

In­vestors didn’t like it. The biotech’s shares tanked 18% in af­ter-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER